Market News AIOpen the app

Telo Genomics revealed a plan to get exclusive rights for AI technology that helps find cancer cells.

DealRead the original at newsfilecorp.com
Neutral

Telo Genomics signed a term sheet to pursue an option for AI cell-detection technology, which could broaden its testing platform. A final license is still pending, and no rights have been granted, so its outlook is unchanged for now.

TELO · Telo Genomics Corp.

AI read · Neutral

The AI's read

The proposed technology could add uses to Telo Genomics' testing platform. But a final license still needs to be negotiated and signed, and the company has no license rights yet. The possible expansion has not changed its business outlook.

Get alerts for TELO

Follow Telo Genomics Corp. (TELO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TELO
Free on the App Store and Google Play, or on the web.